EICHOR
● Not Yet Recruiting
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer
Condition: Endometrial Cancer · Sponsor: University of Oklahoma
About this study
The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).
This description comes directly from the study's public registry record.
Talk to the study team
Lead Gynecology Oncology Nurse · 572-244-0111 · SCC-IIT-Office@ouhsc.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| OU Health Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07737795